# Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% to LUMIGAN® In The Treatment of Chronic Open-Angle Glaucoma

> **NCT04890106** · PHASE3 · COMPLETED · sponsor: **Mankind Pharma Limited** · enrollment: 310 (actual)

## Conditions studied

- Glaucoma, Open-Angle

## Interventions

- **DRUG:** Test - Bimatoprost 0.01% Ophthalmic Solution
- **DRUG:** Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution)

## Key facts

- **NCT ID:** NCT04890106
- **Lead sponsor:** Mankind Pharma Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-02
- **Primary completion:** 2022-08-11
- **Final completion:** 2022-08-11
- **Target enrollment:** 310 (ACTUAL)
- **Last updated:** 2022-12-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04890106

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04890106, "Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% to LUMIGAN® In The Treatment of Chronic Open-Angle Glaucoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04890106. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*